Century Therapeutics ( NASDAQ:IPSC – Get Rating ) ‘s stock had its 'buy' rating restated by research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $17.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 448.39% from the company's previous close. A number of other equities analysts have also weighed in on IPSC. Chardan Capital restated a 'buy' rating and issued a $19.00 price objective on shares of Century Therapeutics in a report on Wednesday, March 22nd.

https://www.dailypolitical.com/2023/04/17/hc-wainwright-reaffirms-buy-rating-for-century-therapeutics-nasdaqipsc.html

#dailypolitical